' 
SCIENTIFIC SCORE
Most Likely Effective
Based on 8 Researches
7.5
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
10
Total Fat
1 g
1%
Saturated Fat
0 g
0%
Trans Fat
0 g
**
Polyunsaturated Fat
0.5 g
**
Monounsaturated Fat
0 g
**
Cholesterol
10 mg
3%
Omega-3 Fish Oil
1000 mg
**
EPA (Eicosapentaenoic Acid)
180 mg
**
DHA (Docosahexaenoic Acid)
120 mg
**
Top Medical Research Studies
9
Eicosapentaenoic Acid reduces stroke risk
Omega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183 291 Participants From 29 Prospective Studies.
Highly relevant to stroke prevention
We investigated the relationship between eicosapentaenoic acid (EPA) levels and stroke risk by pooling data from 29 international studies, involving over 183,000 participants. Our goal was to understand how circulating and tissue omega-3 fatty acid levels, specifically EPA, affect the occurrence of different types of stroke, including total, ischemic, and hemorrhagic strokes.
Our findings revealed that higher levels of EPA are linked to a lower risk of both total and ischemic strokes. For participants who had the highest levels of EPA, there was a 17% lower incidence of total strokes compared to those with the lowest levels, and an 18% reduction in ischemic strokes. This suggests that increasing EPA intake could be beneficial in reducing the risk of these stroke types.
However, it's important to note that EPA showed no significant relationship with hemorrhagic stroke risk. This indicates that while EPA may help prevent some stroke types, it does not appear to reduce the risk of bleeding strokes. These results were consistent across various demographics, regardless of whether participants had a history of atrial fibrillation or existing cardiovascular disease. Overall, our study presents strong evidence that EPA can be a valuable addition to dietary strategies aimed at reducing stroke risks.
Our findings revealed that higher levels of EPA are linked to a lower risk of both total and ischemic strokes. For participants who had the highest levels of EPA, there was a 17% lower incidence of total strokes compared to those with the lowest levels, and an 18% reduction in ischemic strokes. This suggests that increasing EPA intake could be beneficial in reducing the risk of these stroke types.
However, it's important to note that EPA showed no significant relationship with hemorrhagic stroke risk. This indicates that while EPA may help prevent some stroke types, it does not appear to reduce the risk of bleeding strokes. These results were consistent across various demographics, regardless of whether participants had a history of atrial fibrillation or existing cardiovascular disease. Overall, our study presents strong evidence that EPA can be a valuable addition to dietary strategies aimed at reducing stroke risks.
Read More
7
Impact on stroke unclear
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Moderate relevance to stroke
We explored the effects of eicosapentaenoic acid, commonly known as icosapent ethyl, on stroke among patients with high cardiovascular risk. This analysis was part of the REDUCE-IT trial, which involved statin-treated patients who had elevated triglycerides and baseline low-density lipoprotein cholesterol (LDL-C) levels.
Participants were divided into two groups: one receiving icosapent ethyl, taken twice daily, and the other receiving a placebo. When we looked specifically at the data for patients with low LDL-C levels (less than 55 mg/dL), we found that those treated with icosapent ethyl had a lower occurrence of the primary composite endpoint, which included stroke, compared to those in the placebo group.
In patients with higher LDL-C (55 mg/dL or more), a similar trend was observed, where the rate of primary composite outcomes, including strokes, was also lower in those receiving icosapent ethyl. Importantly, we noted that the treatment seemed effective in reducing cardiovascular events regardless of initial LDL-C levels, suggesting a beneficial role even for those with controlled cholesterol levels.
However, while the results showed promise for the overall reduction of cardiovascular events, including strokes, we acknowledge that the specific impact of icosapent ethyl on stroke alone remains part of a broader set of outcomes. Thus, while it seems to help reduce risks, we should be cautious in attributing benefits directly to stroke without further focused studies.
Participants were divided into two groups: one receiving icosapent ethyl, taken twice daily, and the other receiving a placebo. When we looked specifically at the data for patients with low LDL-C levels (less than 55 mg/dL), we found that those treated with icosapent ethyl had a lower occurrence of the primary composite endpoint, which included stroke, compared to those in the placebo group.
In patients with higher LDL-C (55 mg/dL or more), a similar trend was observed, where the rate of primary composite outcomes, including strokes, was also lower in those receiving icosapent ethyl. Importantly, we noted that the treatment seemed effective in reducing cardiovascular events regardless of initial LDL-C levels, suggesting a beneficial role even for those with controlled cholesterol levels.
However, while the results showed promise for the overall reduction of cardiovascular events, including strokes, we acknowledge that the specific impact of icosapent ethyl on stroke alone remains part of a broader set of outcomes. Thus, while it seems to help reduce risks, we should be cautious in attributing benefits directly to stroke without further focused studies.
Read More
7
Eicosapentaenoic acid links to stroke
Intake of marine and plant-derived n-3 fatty acids and development of atherosclerotic cardiovascular disease in the Danish Diet, Cancer and Health cohort.
Study focuses on stroke risk.
We explored a significant study looking at the role of eicosapentaenoic acid (EPA), a type of marine n-3 fatty acid, in relation to atherosclerotic cardiovascular disease (ASCVD) and acute major ischemic events, which includes strokes. The research followed 53,909 participants over a median period of 13.5 years to determine how their intake of EPA, along with other n-3 fatty acids, impacted their heart health and risk of stroke.
During the study, researchers found that those who had a high intake of EPA and docosahexaenoic acid (DHA) showed a lower risk of developing ASCVD. This was particularly true for major ischemic events, which are critical conditions such as strokes. However, the results were different for alpha-linolenic acid (ALA), a plant-derived omega-3 fatty acid, which did not seem to have any beneficial effects on stroke risk in this population.
It's interesting to note that the use of a validated food frequency questionnaire allowed participants to self-report their dietary intake, and the results were adjusted for various risk factors. Overall, the findings suggest that while EPA (and DHA) intake is linked to better outcomes regarding heart disease and stroke risks, ALA did not show the same protective effects.
During the study, researchers found that those who had a high intake of EPA and docosahexaenoic acid (DHA) showed a lower risk of developing ASCVD. This was particularly true for major ischemic events, which are critical conditions such as strokes. However, the results were different for alpha-linolenic acid (ALA), a plant-derived omega-3 fatty acid, which did not seem to have any beneficial effects on stroke risk in this population.
It's interesting to note that the use of a validated food frequency questionnaire allowed participants to self-report their dietary intake, and the results were adjusted for various risk factors. Overall, the findings suggest that while EPA (and DHA) intake is linked to better outcomes regarding heart disease and stroke risks, ALA did not show the same protective effects.
Read More
Most Useful Reviews
9.5
Reduces stroke risk
The work concluded that a high level of Omega-3 polyunsaturated fatty acids in blood reduces the risk of minor stroke by 40%. Omega-3 acids clear the walls of blood vessels from excess "bad" cholesterol, preventing “cholesterol plaques” and improving blood viscosity.
Read More
Most Recommended Products for Stroke
Solaray Buffered Super Bio Vitamin C
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 2 Reviews
9.2
Natrol Melatonin
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Excellent
Based on 2 Reviews
9.2
Nature's Way Black Elderberry
SCIENTIFIC SCORE
No researches found
N/A
USERS' SCORE
Very Good
Based on 2 Reviews
8.9
Medical Researches
SCIENTIFIC SCORE
Most Likely Effective
Based on 8 Researches
7.5
9
Eicosapentaenoic Acid reduces stroke risk
Omega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183 291 Participants From 29 Prospective Studies.
Highly relevant to stroke prevention
We investigated the relationship between eicosapentaenoic acid (EPA) levels and stroke risk by pooling data from 29 international studies, involving over 183,000 participants. Our goal was to understand how circulating and tissue omega-3 fatty acid levels, specifically EPA, affect the occurrence of different types of stroke, including total, ischemic, and hemorrhagic strokes.
Our findings revealed that higher levels of EPA are linked to a lower risk of both total and ischemic strokes. For participants who had the highest levels of EPA, there was a 17% lower incidence of total strokes compared to those with the lowest levels, and an 18% reduction in ischemic strokes. This suggests that increasing EPA intake could be beneficial in reducing the risk of these stroke types.
However, it's important to note that EPA showed no significant relationship with hemorrhagic stroke risk. This indicates that while EPA may help prevent some stroke types, it does not appear to reduce the risk of bleeding strokes. These results were consistent across various demographics, regardless of whether participants had a history of atrial fibrillation or existing cardiovascular disease. Overall, our study presents strong evidence that EPA can be a valuable addition to dietary strategies aimed at reducing stroke risks.
Our findings revealed that higher levels of EPA are linked to a lower risk of both total and ischemic strokes. For participants who had the highest levels of EPA, there was a 17% lower incidence of total strokes compared to those with the lowest levels, and an 18% reduction in ischemic strokes. This suggests that increasing EPA intake could be beneficial in reducing the risk of these stroke types.
However, it's important to note that EPA showed no significant relationship with hemorrhagic stroke risk. This indicates that while EPA may help prevent some stroke types, it does not appear to reduce the risk of bleeding strokes. These results were consistent across various demographics, regardless of whether participants had a history of atrial fibrillation or existing cardiovascular disease. Overall, our study presents strong evidence that EPA can be a valuable addition to dietary strategies aimed at reducing stroke risks.
Read More
8
Eicosapentaenoic acid and stroke
Exploring Genetic Associations of 3 Types of Risk Factors With Ischemic Stroke: An Integrated Bioinformatics Study.
Indicates potential risk factors
We explored the connection between eicosapentaenoic acid, a type of omega-3 fatty acid, and the risk of ischemic stroke (IS). The study utilized genetic analysis and data from various sources to determine if eicosapentaenoic acid directly affects stroke outcomes.
Our findings indicated that eicosapentaenoic acid was associated with an increased risk of IS, showing an odds ratio of 2.36. This suggests that higher levels of this fatty acid might correlate with a greater chance of experiencing a stroke.
However, it's important to note that while the results are interesting, they do not clearly establish eicosapentaenoic acid as a beneficial treatment for stroke prevention. Instead, they highlight a potential risk factor that requires further research.
We identified 73 genes associated with blood pressure and circulating lipids in the context of IS, emphasizing the complex interplay between genetics, nutrition, and stroke risk. This study helps advance our understanding of how dietary components may influence stroke dynamics, opening pathways for future investigations.
Our findings indicated that eicosapentaenoic acid was associated with an increased risk of IS, showing an odds ratio of 2.36. This suggests that higher levels of this fatty acid might correlate with a greater chance of experiencing a stroke.
However, it's important to note that while the results are interesting, they do not clearly establish eicosapentaenoic acid as a beneficial treatment for stroke prevention. Instead, they highlight a potential risk factor that requires further research.
We identified 73 genes associated with blood pressure and circulating lipids in the context of IS, emphasizing the complex interplay between genetics, nutrition, and stroke risk. This study helps advance our understanding of how dietary components may influence stroke dynamics, opening pathways for future investigations.
Read More
8
Eicosapentaenoic Acid and Stroke
Fatty Acids and Lipid Paradox-Neuroprotective Biomarkers in Ischemic Stroke.
Limited treatment focus noted
We explored the impact of eicosapentaenoic acid (EPA) on patients suffering from ischemic stroke, a condition that accounts for a significant portion of stroke cases worldwide. By analyzing data from 298 patients, we delved into how the lipid profile, particularly fatty acids like EPA, might influence recovery after a stroke.
Our findings revealed an interesting relationship between certain lipids and stroke outcomes. We noted a negative correlation between the severity of stroke at admission and the levels of total cholesterol and triglycerides. More importantly, the ratio of eicosapentaenoic acid to arachidonic acid was also found to negatively correlate with worse prognostic factors. Conversely, a higher ratio of docosahexaenoic acid to eicosapentaenoic acid showed a positive correlation with better outcomes.
These results suggest that while the overall lipids often paint a complicated picture, eicosapentaenoic acid could potentially offer neuroprotective benefits for patients experiencing severe ischemic stroke. It provides new insights into how specific fatty acids might play a pivotal role in recovery and functional outcomes after stroke, although it's essential to note that the study does not focus on EPA as a direct treatment approach.
Our findings revealed an interesting relationship between certain lipids and stroke outcomes. We noted a negative correlation between the severity of stroke at admission and the levels of total cholesterol and triglycerides. More importantly, the ratio of eicosapentaenoic acid to arachidonic acid was also found to negatively correlate with worse prognostic factors. Conversely, a higher ratio of docosahexaenoic acid to eicosapentaenoic acid showed a positive correlation with better outcomes.
These results suggest that while the overall lipids often paint a complicated picture, eicosapentaenoic acid could potentially offer neuroprotective benefits for patients experiencing severe ischemic stroke. It provides new insights into how specific fatty acids might play a pivotal role in recovery and functional outcomes after stroke, although it's essential to note that the study does not focus on EPA as a direct treatment approach.
Read More
7
Impact on stroke unclear
Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial.
Moderate relevance to stroke
We explored the effects of eicosapentaenoic acid, commonly known as icosapent ethyl, on stroke among patients with high cardiovascular risk. This analysis was part of the REDUCE-IT trial, which involved statin-treated patients who had elevated triglycerides and baseline low-density lipoprotein cholesterol (LDL-C) levels.
Participants were divided into two groups: one receiving icosapent ethyl, taken twice daily, and the other receiving a placebo. When we looked specifically at the data for patients with low LDL-C levels (less than 55 mg/dL), we found that those treated with icosapent ethyl had a lower occurrence of the primary composite endpoint, which included stroke, compared to those in the placebo group.
In patients with higher LDL-C (55 mg/dL or more), a similar trend was observed, where the rate of primary composite outcomes, including strokes, was also lower in those receiving icosapent ethyl. Importantly, we noted that the treatment seemed effective in reducing cardiovascular events regardless of initial LDL-C levels, suggesting a beneficial role even for those with controlled cholesterol levels.
However, while the results showed promise for the overall reduction of cardiovascular events, including strokes, we acknowledge that the specific impact of icosapent ethyl on stroke alone remains part of a broader set of outcomes. Thus, while it seems to help reduce risks, we should be cautious in attributing benefits directly to stroke without further focused studies.
Participants were divided into two groups: one receiving icosapent ethyl, taken twice daily, and the other receiving a placebo. When we looked specifically at the data for patients with low LDL-C levels (less than 55 mg/dL), we found that those treated with icosapent ethyl had a lower occurrence of the primary composite endpoint, which included stroke, compared to those in the placebo group.
In patients with higher LDL-C (55 mg/dL or more), a similar trend was observed, where the rate of primary composite outcomes, including strokes, was also lower in those receiving icosapent ethyl. Importantly, we noted that the treatment seemed effective in reducing cardiovascular events regardless of initial LDL-C levels, suggesting a beneficial role even for those with controlled cholesterol levels.
However, while the results showed promise for the overall reduction of cardiovascular events, including strokes, we acknowledge that the specific impact of icosapent ethyl on stroke alone remains part of a broader set of outcomes. Thus, while it seems to help reduce risks, we should be cautious in attributing benefits directly to stroke without further focused studies.
Read More
7
Icosapent ethyl reduces stroke risk
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT.
Relevant but not exclusive to stroke
We investigated the effects of eicosapentaenoic acid, specifically icosapent ethyl (IPE), in relation to stroke and other cardiovascular events in a study called REDUCE-IT. The trial compared IPE to a placebo in patients both with and without a history of atrial fibrillation (AF).
While we found that IPE reduced serious heart-related issues—like cardiovascular death, heart attacks, and strokes—it's important to note that there was an increase in hospitalizations due to AF among those treated with IPE.
In fact, the hospitalization rates for AF were higher in patients who previously had AF, especially those on IPE. Interestingly, the relative risk reductions of stroke and other serious events appeared similar between patients with a history of AF and those without, suggesting that IPE may offer protective benefits against these severe outcomes regardless of AF history.
However, while serious bleeding events were slightly higher among those receiving IPE, this increase wasn’t statistically significant. Thus, we can conclude that IPE has a role in lowering primary cardiovascular risks but may come with some considerations regarding AF and bleeding.
While we found that IPE reduced serious heart-related issues—like cardiovascular death, heart attacks, and strokes—it's important to note that there was an increase in hospitalizations due to AF among those treated with IPE.
In fact, the hospitalization rates for AF were higher in patients who previously had AF, especially those on IPE. Interestingly, the relative risk reductions of stroke and other serious events appeared similar between patients with a history of AF and those without, suggesting that IPE may offer protective benefits against these severe outcomes regardless of AF history.
However, while serious bleeding events were slightly higher among those receiving IPE, this increase wasn’t statistically significant. Thus, we can conclude that IPE has a role in lowering primary cardiovascular risks but may come with some considerations regarding AF and bleeding.
Read More
User Reviews
USERS' SCORE
Excellent
Based on 1 Reviews
9.5
9.5
Reduces stroke risk
The work concluded that a high level of Omega-3 polyunsaturated fatty acids in blood reduces the risk of minor stroke by 40%. Omega-3 acids clear the walls of blood vessels from excess "bad" cholesterol, preventing “cholesterol plaques” and improving blood viscosity.
